Literature DB >> 22859584

A multiplex real-time PCR assay for the detection and differentiation of Francisella tularensis subspecies.

Mark K Gunnell1,2, Charity D Lovelace2, Benjamin A Satterfield2, Emily A Moore2, Kim L O'Neill2, Richard A Robison2.   

Abstract

Francisella tularensis is the aetiological agent of tularaemia, a zoonotic disease with worldwide prevalence. F. tularensis is a highly pathogenic organism and has been designated a category A biothreat agent by the Centers for Disease Control and Prevention. Tularaemia is endemic in much of the USA, Europe and parts of Asia. It is transmitted by numerous vectors and vehicles such as deer flies, ticks and rabbits. Currently, there are four recognized subspecies of F. tularensis: tularensis (type A), holarctica (type B), mediasiatica and novicida. Within the type A classification there are two subclassifications, type A.I and A.II, each with a specific geographical distribution across the USA. F. tularensis subsp. holartica (type B) is found in both the USA and Europe. Because of virulence differences among subtypes, it is important that health departments, hospitals and other government agencies are able to quickly identify each subtype. The purpose of this study was to develop a multiplex real-time PCR assay for the identification and discrimination of type A.I, type A.II, type B and novicida subspecies of F. tularensis. The assay was validated using 119 isolates of F. tularensis, three of its nearest neighbours and 14 other bacterial pathogens. This assay proved to be ~98 % successful at identifying the known subspecies of F. tularensis and could prove to be a useful tool in the characterization of this important pathogen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22859584     DOI: 10.1099/jmm.0.046631-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

2.  Challenges of Francisella classification exemplified by an atypical clinical isolate.

Authors:  L M Matz; K Y Kamdar; M E Holder; G A Metcalf; G M Weissenberger; Q Meng; V Vee; Y Han; D M Muzny; R A Gibbs; C L Johnson; P A Revell; J F Petrosino
Journal:  Diagn Microbiol Infect Dis       Date:  2017-12-06       Impact factor: 2.803

3.  Natural Selection in Virulence Genes of Francisella tularensis.

Authors:  Mark K Gunnell; Richard A Robison; Byron J Adams
Journal:  J Mol Evol       Date:  2016-05-13       Impact factor: 2.395

4.  An open-source molecular diagnostic platform approach for outbreak and epidemic preparedness.

Authors:  Devy M Emperador; Laura T Mazzola; Cassandra Kelly-Cirino
Journal:  Afr J Lab Med       Date:  2020-09-28

5.  Ultrasonography and contrast-enhanced CT findings of tularemia in the neck.

Authors:  Serap Doğan; Afra Ekinci; Hayati Demiraslan; Ayşegül Ulu Kılıç; Ertuğrul Mavili; Mustafa Öztürk; Hakan İmamoğlu; Mehmet Doğanay
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

6.  An integrated system for identifying the hidden assassins in traditional medicines containing aristolochic acids.

Authors:  Lan Wu; Wei Sun; Bo Wang; Haiyu Zhao; Yaoli Li; Shaoqing Cai; Li Xiang; Yingjie Zhu; Hui Yao; Jingyuan Song; Yung-Chi Cheng; Shilin Chen
Journal:  Sci Rep       Date:  2015-08-13       Impact factor: 4.379

7.  Serological evidence of Francisella tularensis in febrile patients seeking treatment at remote hospitals, northeastern Kenya, 2014-2015.

Authors:  J Njeru; H Tomaso; K Mertens; K Henning; G Wareth; R Heller; S Kariuki; E M Fèvre; H Neubauer; M W Pletz
Journal:  New Microbes New Infect       Date:  2017-06-03

8.  Differentiation of Francisella tularensis Subspecies and Subtypes.

Authors:  Marilynn A Larson; Khalid Sayood; Amanda M Bartling; Jennifer R Meyer; Clarise Starr; James Baldwin; Michael P Dempsey
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.